title: Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.
abstract: Oseltamivir is a potent, well-tolerated antiviral for the treatment and prophylaxis of influenza. Although no relationship with treatment could be demonstrated, recent reports of abnormal behavior in young individuals with influenza who were receiving oseltamivir have generated renewed interest in the central nervous system (CNS) tolerability of oseltamivir. This single-center, open-label study explored the pharmacokinetics of oseltamivir and oseltamivir carboxylate (OC) in the plasma and cerebrospinal fluid (CSF) of healthy adult volunteers over a 24-hour interval to determine the CNS penetration of both these compounds. Four Japanese and four Caucasian males were enrolled in the study. Oseltamivir and OC concentrations in CSF were low (mean of observed maximum concentrations [C(max)], 2.4 ng/ml [oseltamivir] and 19.0 ng/ml [OC]) versus those in plasma (mean C(max), 115 ng/ml [oseltamivir] and 544 ng/ml [OC]), with corresponding C(max) CSF/plasma ratios of 2.1% (oseltamivir) and 3.5% (OC). Overall exposure to oseltamivir and OC in CSF was also comparatively low versus that in plasma (mean area under the concentration-time curve CSF/plasma ratio, 2.4% [oseltamivir] and 2.9% [OC]). No gross differences in the pharmacokinetics of oseltamivir or OC were observed between the Japanese and Caucasian subjects. Oseltamivir was well tolerated. This demonstrates that the CNS penetration of oseltamivir and OC is low in Japanese and Caucasian adults. Emerging data support the idea that oseltamivir and OC have limited potential to induce or exacerbate CNS adverse events in individuals with influenza. A disease- rather than drug-related effect appears likely.
authors.affiliation: California Clinical Trials, Glendale, California, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Jhee
authors.forename: M
authors.initials: M
authors.lastname: Yen
authors.forename: L
authors.initials: L
authors.lastname: Ereshefsky
authors.forename: M
authors.initials: M
authors.lastname: Leibowitz
authors.forename: M
authors.initials: M
authors.lastname: Schulte
authors.forename: B
authors.initials: B
authors.lastname: Kaeser
authors.forename: L
authors.initials: L
authors.lastname: Boak
authors.forename: A
authors.initials: A
authors.lastname: Patel
authors.forename: G
authors.initials: G
authors.lastname: Hoffmann
authors.forename: E P
authors.initials: EP
authors.lastname: Prinssen
authors.forename: C R
authors.initials: CR
authors.lastname: Rayner
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid*; D044466:Asian People; D002490:Central Nervous System / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid*; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D009975:Orthomyxoviridae / Q000187:drug effects / Q000201:enzymology; D053139:Oseltamivir / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid*; D044465:White People
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D053139:Oseltamivir; D009439:Neuraminidase